NEW YORK (GenomeWeb) – Biocartis announced today that it has partnered with AstraZeneca on a European study designed to obtain faster lung cancer molecular diagnostics results.
As part of the agreement, the firms will begin a prospective lung cancer study using Biocartis' Idylla EGFR mutation test in European countries including Belgium, France, Germany, and Italy.